financetom
Business
financetom
/
Business
/
Kinder Morgan Sees Adjusted EPS Growing to $1.27 During 2025, Topping Analyst Estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kinder Morgan Sees Adjusted EPS Growing to $1.27 During 2025, Topping Analyst Estimates
Dec 9, 2024 2:02 PM

04:41 PM EST, 12/09/2024 (MT Newswires) -- Kinder Morgan ( KMI ) late Monday said it is expecting 2025 adjusted net income of $1.27 per diluted share, up from its current 2024 forecast looking for $1.17.

Analysts polled by FactSet, on average, are looking for $1.18 and 1.25, for fiscal 2024 and 2025, respectively.

The oil and gas pipeline company also said it expects to invest around $2.3 billion in discretionary capital expenditures next year, which would include expansion projects and contributions to joint ventures. The capex will be funded out of internally generated cash flow.

The Kinder Morgan ( KMI ) board of directors are expecting to finalize their 2025 projections at a board meeting next month, expected to coincide with Q4 financial report, scheduled for Jan. 22.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Tesla Offers Free Trial of Full Self-Driving Service in China
Market Chatter: Tesla Offers Free Trial of Full Self-Driving Service in China
Mar 17, 2025
07:22 AM EDT, 03/17/2025 (MT Newswires) -- Tesla (TSLA) is offering a free trial of its Full Self-Driving service in China, Reuters reported Monday, citing the company's Chinese website. According to the report, the free trial period starts Monday and extends through April 16. Tesla did not immediately respond to MT Newswires' request for comment. (Market Chatter news is derived...
Nurix Therapeutics' Blood Cancer Drug Candidate Gets FDA Orphan Drug Designation
Nurix Therapeutics' Blood Cancer Drug Candidate Gets FDA Orphan Drug Designation
Mar 17, 2025
07:25 AM EDT, 03/17/2025 (MT Newswires) -- Nurix Therapeutics ( NRIX ) said Monday that the US Food and Drug Administration has granted orphan drug designation to the company's experimental drug, bexobrutideq, for treating Waldenstrom macroglobulinemia, a type of blood cancer. The company said the drug is currently being evaluated in a phase 1 trial for adults with relapsed or...
Science Applications Fiscal Q4 Adjusted Earnings, Revenue Rise; Fiscal 2026 Guidance Revised
Science Applications Fiscal Q4 Adjusted Earnings, Revenue Rise; Fiscal 2026 Guidance Revised
Mar 17, 2025
07:20 AM EDT, 03/17/2025 (MT Newswires) -- Science Applications International ( SAIC ) reported fiscal Q4 adjusted earnings Monday of $2.57 per diluted share, up from $1.43 a year earlier. Analysts polled by FactSet expected $2.09. Revenue for the quarter ended Jan. 31 was $1.84 billion, up from $1.74 billion a year earlier. Analysts surveyed by FactSet expected $1.82 billion....
GreenFirst Forest Products Q4 Loss Doubles as Sales Fall
GreenFirst Forest Products Q4 Loss Doubles as Sales Fall
Mar 17, 2025
07:26 AM EDT, 03/17/2025 (MT Newswires) -- GreenFirst Forest Products ( ICLTF ) over the weekend said its fourth-quarter loss doubled as sales dropped due to weather-related disruptions that slowed the company's supply chain. The company reported a fourth-quarter net loss from continuing operations of $26.6 million or $1.39 loss per diluted share, compared with a loss of $13.4 million...
Copyright 2023-2026 - www.financetom.com All Rights Reserved